Amneal Pharmaceuticals, Inc. (AMRX)
USD 7.69
(-4.71%)
USD 7.69
(-4.71%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.47 Billion USD | -8.6% |
| 2022 | 3.79 Billion USD | -3.56% |
| 2021 | 3.93 Billion USD | -1.66% |
| 2020 | 4 Billion USD | 9.28% |
| 2019 | 3.66 Billion USD | -15.78% |
| 2018 | 4.35 Billion USD | 224.37% |
| 2017 | 1.34 Billion USD | 10.1% |
| 2016 | 1.21 Billion USD | 20.19% |
| 2015 | 1.01 Billion USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 3.5 Billion USD | 1.55% |
| 2024 Q1 | 3.45 Billion USD | -0.47% |
| 2023 Q3 | 3.68 Billion USD | -0.37% |
| 2023 Q2 | 3.7 Billion USD | 2.05% |
| 2023 FY | 3.47 Billion USD | -8.6% |
| 2023 Q1 | 3.62 Billion USD | -4.55% |
| 2023 Q4 | 3.47 Billion USD | -5.82% |
| 2022 Q4 | 3.79 Billion USD | -1.93% |
| 2022 Q3 | 3.87 Billion USD | -4.14% |
| 2022 Q2 | 4.04 Billion USD | 3.92% |
| 2022 FY | 3.79 Billion USD | -3.56% |
| 2022 Q1 | 3.88 Billion USD | -1.29% |
| 2021 Q4 | 3.93 Billion USD | -0.87% |
| 2021 Q1 | 3.96 Billion USD | -1.15% |
| 2021 Q2 | 4.02 Billion USD | 1.59% |
| 2021 FY | 3.93 Billion USD | -1.66% |
| 2021 Q3 | 3.97 Billion USD | -1.21% |
| 2020 Q3 | 4.03 Billion USD | -0.47% |
| 2020 Q1 | 4.39 Billion USD | 19.77% |
| 2020 Q4 | 4 Billion USD | -0.78% |
| 2020 FY | 4 Billion USD | 9.28% |
| 2020 Q2 | 4.05 Billion USD | -7.61% |
| 2019 Q2 | 4.26 Billion USD | -2.79% |
| 2019 FY | 3.66 Billion USD | -15.78% |
| 2019 Q4 | 3.66 Billion USD | -1.03% |
| 2019 Q3 | 3.7 Billion USD | -13.1% |
| 2019 Q1 | 4.38 Billion USD | 0.73% |
| 2018 Q4 | 4.35 Billion USD | -5.0% |
| 2018 FY | 4.35 Billion USD | 224.37% |
| 2018 Q3 | 4.58 Billion USD | 0.82% |
| 2018 Q2 | 4.54 Billion USD | 234.46% |
| 2018 Q1 | 1.35 Billion USD | 1.26% |
| 2017 Q3 | 1.23 Billion USD | 0.0% |
| 2017 Q1 | - USD | -100.0% |
| 2017 Q4 | 1.34 Billion USD | 8.25% |
| 2017 FY | 1.34 Billion USD | 10.1% |
| 2016 FY | 1.21 Billion USD | 20.19% |
| 2016 Q4 | 1.21 Billion USD | 0.0% |
| 2015 FY | 1.01 Billion USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Bausch Health Companies Inc. | 27.35 Billion USD | 87.303% |
| Catalent, Inc. | 9.75 Billion USD | 64.395% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | -89.251% |
| Elanco Animal Health Incorporated | 14.36 Billion USD | 75.821% |
| Perrigo Company plc | 10.8 Billion USD | 67.874% |
| Teva Pharmaceutical Industries Limited | 43.47 Billion USD | 92.013% |
| Zoetis Inc. | 14.28 Billion USD | 75.693% |